儿科瘤患者的:一个单一机构的回顾性研究
Tina Ho1,2, Christopher Iriarte1,3, Jorge Zuniga3
1Dermatology Section, Division of Immunology, Boston Children's Hospital, Boston, Massachusetts, USA.
Pediatric dermatology
|May 30, 2023
概括
儿科瘤学患者经常由于免疫抑制而发展出困难的. 在活跃的癌症治疗期间,治疗效果较差,只有24%的得到解决,而治疗后的这一比例为63%.
科学领域:
- 皮肤病学 皮肤病学
- 儿科瘤学 儿科瘤学
- 免疫学 免疫学 免疫学
背景情况:
- 儿科瘤学患者经常因为免疫抑制而出现大量和持久的皮肤.
- 对于正在接受活跃癌症治疗的儿科瘤患者和已经完成治疗的患者,关于最佳治疗策略的数据有限.
研究的目的:
- 在波士顿儿童医院的儿科瘤患者10年内分析的临床过程和治疗结果.
- 在接受活跃癌症治疗的患者和已经完成治疗的患者中,比较治疗的有效性.
主要方法:
- 在2011年9月至2021年9月期间,对72名儿科瘤患者进行了单一机构的回顾性研究,这些患者接受了的治疗.
- 纳入标准:皮肤的诊断,至少一次随访,并接受活跃或后活跃的癌症治疗.
- 在活性癌症治疗期间和之后评估治疗方法和有效性.
主要成果:
- 患者的中位数年龄为12岁 (范围为4-18岁);54%的人患有脚,60%的人在呈现时患有5个以上的.
- 只有24.0%接受活跃癌症治疗的患者出现了完全的的消失,而未接受活跃治疗的患者中,这一比例为63.3%.
- 在接受活跃癌症治疗的患者中,56.0%的持续或恶化,而未接受活跃治疗的患者中,13.4%的持续或恶化.
结论:
- 治疗的疗效在接受活跃癌症治疗的儿科瘤患者和已经完成治疗的儿科瘤患者之间有显著差异.
- 这些发现可以帮助临床医生在这个脆弱的患者群体中管理.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:22Bone Marrow Sampling and Transplants
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...